FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
NDA FilingapprovedPixclaraPositive
AI Analysis
Summary
The FDA has approved Telix Pharmaceuticals' Pixclara (floretyrosine F 18), a PET imaging drug for detecting and imaging gliomas (brain cancer). This marks a significant regulatory milestone for the company's diagnostic imaging portfolio.
Outcome Details
FDA approved New Drug Application for Pixclara (floretyrosine F 18) for imaging gliomas
Importance:8/10
Sentiment:
0.95
FDA approvaloncologyPET imagingbrain cancerdiagnostic
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 14, 2026 10:30 AM